Kiadis Pharma appoints Jan Feijen as Chief Operations Officer

Amsterdam, The Netherlands, March 20, 2017, – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing inno­v­a­tive T-cell immunother­a­py treat­ments for blood can­cers and inher­it­ed blood dis­or­ders, today announces the appoint­ment of Jan Feijen as Chief Operations Officer (COO) effec­tive from April 1, 2017.
Jan Feijen brings sig­nif­i­cant pro­fes­sion­al man­age­ment skills and exten­sive expe­ri­ence in man­u­fac­tur­ing, oper­a­tions and project man­age­ment to Kiadis Pharma. He is a sea­soned leader who, most recent­ly, was Vice President Manufacturing and Technical Operations Platform Lead Vaccines and Advanced Therapies at Janssen (Pharmaceutical Companies of Johnson & Johnson). Prior to that he held var­i­ous exec­u­tive and project lead posi­tions at Crucell, Avebe and Gist Brocades. Jan has built and run many clin­i­cal and com­mer­cial man­u­fac­tur­ing facil­i­ties and oper­a­tions across mul­ti­ple sites in Europe, the US and Asia. In his role as COO at Kiadis Pharma, Jan will be respon­si­ble for man­u­fac­tur­ing, sup­ply chain, QA and project man­age­ment.

Arthur Lahr, CEO des­ig­nate of Kiadis Pharma, said: “We are very pleased that an indus­try leader like Jan has accept­ed this oppor­tu­ni­ty to join Kiadis Pharma. His vast expe­ri­ence in phar­ma pro­duc­tion pre­cedes him, and his expe­ri­ence in run­ning com­plex, just-in-time logis­tics will be of great val­ue in scal­ing up our patient spe­cif­ic sup­ply chain. I have known Jan for many years and he is one of those few peo­ple that can thrive in both large and small orga­ni­za­tions. I am con­fi­dent that Jan will ensure the smooth run­ning of our Phase III oper­a­tions and will suc­cess­ful­ly set up and run our com­mer­cial sup­ply chain.

Commenting on his appoint­ment Jan Feijen said: “I am very pleased to be join­ing Kiadis Pharma at this impor­tant time in its devel­op­ment. With the Company’s piv­otal Phase III tri­al with ATIR101™ now under­way, it is vital that the nec­es­sary steps are tak­en to ensure every­thing con­tin­ues to run smooth­ly and that we have all logis­tics in hand ready to roll out com­mer­cial­ly in the future.

Leave a Reply

Your email address will not be published. Required fields are marked *